307 related articles for article (PubMed ID: 18275073)
1. Identification of local and circulating cancer stem cells in human liver cancer.
Yang ZF; Ngai P; Ho DW; Yu WC; Ng MN; Lau CK; Li ML; Tam KH; Lam CT; Poon RT; Fan ST
Hepatology; 2008 Mar; 47(3):919-28. PubMed ID: 18275073
[TBL] [Abstract][Full Text] [Related]
2. Significance of CD90+ cancer stem cells in human liver cancer.
Yang ZF; Ho DW; Ng MN; Lau CK; Yu WC; Ngai P; Chu PW; Lam CT; Poon RT; Fan ST
Cancer Cell; 2008 Feb; 13(2):153-66. PubMed ID: 18242515
[TBL] [Abstract][Full Text] [Related]
3. The Notch pathway promotes the cancer stem cell characteristics of CD90+ cells in hepatocellular carcinoma.
Luo J; Wang P; Wang R; Wang J; Liu M; Xiong S; Li Y; Cheng B
Oncotarget; 2016 Feb; 7(8):9525-37. PubMed ID: 26848615
[TBL] [Abstract][Full Text] [Related]
4. Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells.
Liu S; Li N; Yu X; Xiao X; Cheng K; Hu J; Wang J; Zhang D; Cheng S; Liu S
Gastroenterology; 2013 May; 144(5):1031-1041.e10. PubMed ID: 23376424
[TBL] [Abstract][Full Text] [Related]
5. Evidence of CD90+CXCR4+ cells as circulating tumor stem cells in hepatocellular carcinoma.
Zhu L; Zhang W; Wang J; Liu R
Tumour Biol; 2015 Jul; 36(7):5353-60. PubMed ID: 25672610
[TBL] [Abstract][Full Text] [Related]
6. Identification of tumor-initiating cells in a canine hepatocellular carcinoma cell line.
Michishita M; Ezaki S; Ogihara K; Naya Y; Azakami D; Nakagawa T; Sasaki N; Arai T; Shida T; Takahashi K
Res Vet Sci; 2014 Apr; 96(2):315-22. PubMed ID: 24534130
[TBL] [Abstract][Full Text] [Related]
7. Identification of CD90 as a marker for lung cancer stem cells in A549 and H446 cell lines.
Yan X; Luo H; Zhou X; Zhu B; Wang Y; Bian X
Oncol Rep; 2013 Dec; 30(6):2733-40. PubMed ID: 24101104
[TBL] [Abstract][Full Text] [Related]
8. Improved method increases sensitivity for circulating hepatocellular carcinoma cells.
Liu HY; Qian HH; Zhang XF; Li J; Yang X; Sun B; Ma JY; Chen L; Yin ZF
World J Gastroenterol; 2015 Mar; 21(10):2918-25. PubMed ID: 25780289
[TBL] [Abstract][Full Text] [Related]
9. Visualization of stem cell features in human hepatocellular carcinoma reveals in vivo significance of tumor-host interaction and clinical course.
Muramatsu S; Tanaka S; Mogushi K; Adikrisna R; Aihara A; Ban D; Ochiai T; Irie T; Kudo A; Nakamura N; Nakayama K; Tanaka H; Yamaoka S; Arii S
Hepatology; 2013 Jul; 58(1):218-28. PubMed ID: 23447025
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease.
Bahnassy AA; Zekri AR; El-Bastawisy A; Fawzy A; Shetta M; Hussein N; Omran D; Ahmed AA; El-Labbody SS
World J Gastroenterol; 2014 Dec; 20(48):18240-8. PubMed ID: 25561791
[TBL] [Abstract][Full Text] [Related]
11. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma.
Yamashita T; Honda M; Nakamoto Y; Baba M; Nio K; Hara Y; Zeng SS; Hayashi T; Kondo M; Takatori H; Yamashita T; Mizukoshi E; Ikeda H; Zen Y; Takamura H; Wang XW; Kaneko S
Hepatology; 2013 Apr; 57(4):1484-97. PubMed ID: 23174907
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling of liver cancer stem cells by RNA-sequencing.
Ho DW; Yang ZF; Yi K; Lam CT; Ng MN; Yu WC; Lau J; Wan T; Wang X; Yan Z; Liu H; Zhang Y; Fan ST
PLoS One; 2012; 7(5):e37159. PubMed ID: 22606345
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of CD90 and CD14 stem cell markers in malignant breast cancer cell lines.
Lobba AR; Forni MF; Carreira AC; Sogayar MC
Cytometry A; 2012 Dec; 81(12):1084-91. PubMed ID: 23090904
[TBL] [Abstract][Full Text] [Related]
14. Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer.
Chen WC; Chang YS; Hsu HP; Yen MC; Huang HL; Cho CY; Wang CY; Weng TY; Lai PT; Chen CS; Lin YJ; Lai MD
Oncotarget; 2015 Dec; 6(40):42923-37. PubMed ID: 26556861
[TBL] [Abstract][Full Text] [Related]
15. Investigation of diagnostic utility and expression profiles of stem cell markers (CD133 and CD90) in hepatocellular carcinoma, small cell dysplasia, and cirrhosis.
Yilmaz G; Akyol G; Cakir A; Ilhan M
Pathol Res Pract; 2014 Jul; 210(7):419-25. PubMed ID: 24702884
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype.
Jiang J; Zhang Y; Chuai S; Wang Z; Zheng D; Xu F; Zhang Y; Li C; Liang Y; Chen Z
Oncogene; 2012 Feb; 31(6):671-82. PubMed ID: 21743497
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of combination of CD90 and OCT4 for hepatocellular carcinoma after curative resection.
Zhao RC; Zhou J; Chen KF; Gong J; Liu J; He JY; Guan P; Li B; Qin Y
Neoplasma; 2016; 63(2):288-98. PubMed ID: 26674131
[TBL] [Abstract][Full Text] [Related]
18. Dysadherin can enhance tumorigenesis by conferring properties of stem-like cells to hepatocellular carcinoma cells.
Park JR; Kim RJ; Lee YK; Kim SR; Roh KJ; Oh SH; Kong G; Kang KS; Nam JS
J Hepatol; 2011 Jan; 54(1):122-31. PubMed ID: 20952084
[TBL] [Abstract][Full Text] [Related]
19. CD90 and CD110 correlate with cancer stem cell potentials in human T-acute lymphoblastic leukemia cells.
Yamazaki H; Nishida H; Iwata S; Dang NH; Morimoto C
Biochem Biophys Res Commun; 2009 May; 383(2):172-7. PubMed ID: 19341705
[TBL] [Abstract][Full Text] [Related]
20. Surface markers of hepatocellular cancer stem cells and their clinical potential.
Feng D; Wang N; Hu J; Li W
Neoplasma; 2014; 61(5):505-13. PubMed ID: 24712843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
